Tumor necrosis factor receptor-derived peptide analogues
CA 2291963 C · Owner: The Trustees Of The University Of Pennsylvania · Inventors: Takasaki, Wataru; Murali, Ramachandran; Greene, Mark I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to peptides and peptide analogues designed from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. In particular, it relates to cyclic peptides and peptide analogues designed from a binding loop of TNF-R which inhibit TNF binding to its cellular receptors, and methods of making and using such compounds to inhibit the biological activities of TNF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 29, 1998 and granted April 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 29, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 29, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.